Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Rani Therapeutics to Participate in Upcoming September Conferences

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing